Evidence map›Paper›PMID 24886841›Full record

ArticlePloS one2014

High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function.

Anke Bill, Elizabeth M Rosethorne, Toby C Kent, Lindsay Fawcett, Lynn Burchell, Michiel T van Diepen, Anthony Marelli, Sergey Batalov, Loren Miraglia, Anthony P Orth and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Anke BillDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America.
Elizabeth M RosethorneRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Toby C KentRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Lindsay FawcettRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Lynn BurchellRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Michiel T van DiepenRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Anthony MarelliInfectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America.
Sergey BatalovInfectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America.
Loren MiragliaInfectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America.
Anthony P OrthInfectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America.
Nicole A RenaudDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America.
Steven J CharltonRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
Martin GoslingRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
L Alex GaitherDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America.
Paul J Groot-KormelinkRespiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom; Musculoskeletal Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Novartis (United Kingdom) · GBGenomics Institute of the Novartis Research Foundation · USPathways Behavioral Services · USNovartis (Switzerland) · CHNovartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human prostacyclin receptor (hIP receptor) is a seven-transmembrane G protein-coupled receptor (GPCR) that plays a critical role in vascular smooth muscle relaxation and platelet aggregation. hIP receptor dysfunction has been implicated in numerous cardiovascular abnormalities, including myocardial infarction, hypertension, thrombosis and atherosclerosis. Genomic sequencing has discovered several genetic variations in the PTGIR gene coding for hIP receptor, however, its structure-function relationship has not been sufficiently explored. Here we set out to investigate the applicability of high throughput random mutagenesis to study the structure-function relationship of hIP receptor. While chemical mutagenesis was not suitable to generate a mutagenesis library with sufficient coverage, our data demonstrate error-prone PCR (epPCR) mediated mutagenesis as a valuable method for the unbiased screening of residues regulating hIP receptor function and expression. Here we describe the generation and functional characterization of an epPCR derived mutagenesis library compromising >4000 mutants of the hIP receptor. We introduce next generation sequencing as a useful tool to validate the quality of mutagenesis libraries by providing information about the coverage, mutation rate and mutational bias. We identified 18 mutants of the hIP receptor that were expressed at the cell surface, but demonstrated impaired receptor function. A total of 38 non-synonymous mutations were identified within the coding region of the hIP receptor, mapping to 36 distinct residues, including several mutations previously reported to affect the signaling of the hIP receptor. Thus, our data demonstrates epPCR mediated random mutagenesis as a valuable and practical method to study the structure-function relationship of GPCRs.

Indexed as

High-Throughput Nucleotide SequencingAmino AcidsComputer SimulationHEK293 CellsHumansHydroxylamineMutagenesisMutationMutation RatePolymerase Chain ReactionReceptors, EpoprostenolReceptors, ProstaglandinAmino AcidsHydroxylaminePTGIR protein, humanReceptors, EpoprostenolReceptors, Prostaglandin

Identifiers

PMID24886841
PMCPMC4041722
OpenAlexW2094058089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.